RxDoctor Payments Data

Paul Sullivan, DO

Family Medicine · West Hartford, CTNPI 1740200377

Payments from drug & device makers

$1,114in general payments, 2019–2025

Across 72 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$198
  • AstraZeneca$174
  • Johnson & Johnson$152
  • GSK$101
  • Amgen$97
  • Pfizer$94
  • plus $296 from 10 others

What the payments were for

  • Food & beverage$92083%
  • Education$19417%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,114 in reported general payments places this provider in the 70th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$49,840
Medicare patients
121
Services billed
510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide143$157,292
JardianceEmpagliflozin68$107,298
JanuviaSitagliptin Phosphate39$57,243
EliquisApixaban39$47,120
Tresiba Flextouch U-100Insulin Degludec81$44,023
FarxigaDapagliflozin Propanediol32$42,034
TradjentaLinagliptin23$25,211
ProliaDenosumab13$22,801
Breo ElliptaFluticasone/Vilanterol49$21,511
JanumetSitagliptin Phos/Metformin Hcl12$16,176
Janumet XrSitagliptin Phos/Metformin Hcl17$15,530
XareltoRivaroxaban17$15,461
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,906
SymbicortBudesonide/Formoterol Fumarate31$12,337
LinzessLinaclotide16$11,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$198$157,292143 claims
Boehringer IngelheimJardiance, Tradjenta$19$132,50991 claims
MerckJanuvia, Janumet, Janumet Xr$24$88,95068 claims
AstraZenecaFarxiga, Symbicort$174$54,37063 claims
PfizerEliquis$94$47,12039 claims
GSKBreo Ellipta, Trelegy Ellipta$101$36,41871 claims
AmgenProlia$97$22,80113 claims
Johnson & JohnsonXarelto$152$15,46117 claims
AbbVieLinzess, Synthroid$86$15,00639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 588 family medicine providers in Connecticut.

Other family medicine in West Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →